Page last updated: 2024-08-21

hydrazine and Leukemia, Myeloid, Acute

hydrazine has been researched along with Leukemia, Myeloid, Acute in 64 studies

Research

Studies (64)

TimeframeStudies, this research(%)All Research%
pre-19907 (10.94)18.7374
1990's0 (0.00)18.2507
2000's8 (12.50)29.6817
2010's33 (51.56)24.3611
2020's16 (25.00)2.80

Authors

AuthorsStudies
Cui, S; Si, Y; Wang, J; Wang, Y; Yin, X; Yu, L1
Biemond, BJ; Boersma, RS; Chalandon, Y; de Weerdt, O; Deeren, D; Efthymiou, A; Fehr, M; Graux, C; Gregor, M; Heim, D; Janssen, JJWM; Jongen-Lavrencic, M; Klein, SK; Legdeur, MCJC; Löwenberg, B; Manz, M; Ossenkoppele, GJ; Pabst, T; Sinnige, HAM; Spertini, O; Stüssi, G; Tick, LW; van der Poel, MWM; van Norden, Y; van Obbergh, F; van Sluis, G; Westerweel, PE1
Bekker-Jensen, DB; Blume-Jensen, P; Eguchi, A; Emdal, KB; Itzykson, R; Kazi, JU; Masson, K; Nilsson, H; Olsen, JV; Palacio-Escat, N; Puissant, A; Rönnstrand, L; Saez-Rodriguez, J; Wigerup, C1
Grosicki, S; Lawniczek, T; Mittelman, M; Platzbecker, U; Selleslag, D; Zhu, Z1
Chavez, J; Cubitt, CL; Dawson, JL; Komrokji, R; Lancet, JE; List, AF; Padron, E; Sallman, DA; Shah, BD; Sullivan, DM; Sweet, K; Turner, JG; Zhou, J1
Abboud, CN; Abboud, R; Chendamarai, E; DiPersio, JF; Ghobadi, A; Pusic, I; Rettig, MP; Riedell, PA; Schroeder, MA; Stockerl-Goldstein, K; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P1
Prasad, V; Tao, D1
Advani, A; Barot, SV; Carraway, HE; Kalaycio, M; Kerr, C; Kuzmanovic, T; Lee, S; Lichtin, A; Maciejewski, JP; Patel, BJ; Patel, S; Przychodzen, BP; Radivoyevitch, T; Sekeres, MA; Thota, S1
Al Ali, N; Duong, VH; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Sallman, D; Zhang, L1
Artz, AS; Bishop, M; Cooperrider, JH; Fulton, N; Kosuri, S; Larson, RA; Liu, H; Stock, W1
Babushok, DV; Sun, L1
Cerny, J; Lazarus, HM; Litzow, M; Rowe, JM; Rybka, W; Strickland, SA; Tallman, MS; Wang, XV1
Amberg, S; Bokemeyer, C; Christine Wilke, A; Chromik, J; Deppermann, U; Fiedler, W; Ganser, A; Heuser, M; Janning, M; Kebenko, M; Kranich, AL; Modemann, F; Schlipfenbacher, V; Serve, H; Theile, S; Thol, F1
Abdel-Wahab, O; Alvarez, K; Chung, SS; Gönen, M; Klimek, VM; Mi, X; Paffenholz, SV; Park, JH; Penson, AV; Rampal, RK; Sen, F; Sigler, A; Stein, EM; Tallman, MS; Taylor, J1
Albitar, M; Barranta, E; Calvo, KR; Dunbar, CE; Feng, X; Giudice, V; Groarke, E; Gutierrez-Rodrigues, F; Kajigaya, S; Lotter, J; Olnes, MJ; Parikh, AR; Patel, BA; Scheinberg, P; Shalhoub, R; Townsley, DM; Vicente, A; Weinstein, B; Winkler, T; Wu, CO; Young, NS1
Acuña-Cruz, E; Barragán, E; Bergua, JM; Boluda, B; Cano-Ferri, I; Martín-Herreros, B; Martínez Sánchez, MP; Martínez-Cuadrón, D; Martínez-López, J; Megías-Vericat, JE; Montesinos, P; Rodríguez-Veiga, R; Sanz, M; Sargas, C; Sempere, A; Serrano, A; Suárez-Varela, S; Torrent, A; Torres-Miñana, L; Vives, S1
Andreeff, M; Baz, R; Carlson, R; Gabrail, N; Garzon, R; Gutierrez, M; Kashyap, T; Kauffman, M; Klebanov, B; Mau-Sorensen, PM; Rashal, T; Saint-Martin, JR; Savoie, L; Savona, M; Shacham, S; Stone, R; Unger, TJ; Wagner-Johnston, N; Yee, K1
Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N1
He, Z; Hu, Y; Huang, P; Li, Y; Liu, J; Liu, P; Lu, W; Wang, J; Wen, S1
Beck, JF; Becker, S; Ebert, F; Lauterjung, ML; Marx, C; Sonnemann, J; Zimmermann, M1
Afanasyev, B; Anagnostopoulos, A; Brenner, B; Denzlinger, C; Garcia-Delgado, R; Grosicki, S; Mittelman, M; Nagler, A; Platzbecker, U; Portella, MSO; Rossi, G; Selleslag, D; Wong, RSM; Zhu, Z1
Shastri, A; Verma, AK1
Brunetti, L; Buckley, DL; Falini, B; Gionfriddo, I; Goodell, MA; Gundry, MC; Guzman, AG; Huang, YH; Kornblau, SM; Lin, CY; Martelli, MP; Mezzasoma, F; Milano, F; Nabet, B; Ramabadran, R; Sorcini, D; Sportoletti, P1
Edwards, H; Ge, Y; Lin, H; Liu, S; Luedtke, DA; Su, Y; Taub, JW; Wang, Y1
Buckstein, R1
Estey, EH; Percival, MM1
Dama, P; Fulton, N; Kline, J; Liu, H; Tang, M1
Cardamone, D; Frey, NV; Glaser, L; Kricka, LJ; Milone, MC1
Pathak, S; Roth, M; Steidl, U; Verma, A1
Bhagat, T; Braunschweig, I; Roth, M; Schinke, C; Steidl, U; Tamari, R; Verma, A; Will, B1
Bearss, D; Bhalla, KN; Devaraj, SG; Fiskus, W; Iyer, SP; Liu, K; Portier, BP; Shah, B; Sharma, S1
Amin, S; Colledge, AL; Dick, TE; Fox, TE; Hengst, JA; Kale, VP; Kester, M; Loughran, TP; Sharma, A; Sung, SS; Wang, HG; Yun, JK1
Bhatnagar, B; Blum, W; Devine, S; Garzon, R; Hofstetter, J; Kauffman, M; Klisovic, R; Marcucci, G; Phelps, MA; Ranganathan, P; Santhanam, R; Shacham, S; Vasu, S; Walker, A; Walsh, K; Yu, X1
Adamia, S; Berezovskaya, A; Chen, WC; Christie, AL; Conway, AS; Etchin, J; Galinsky, IA; Kauffman, M; Kentsis, A; Klebanov, B; Kung, AL; Landesman, Y; Le, BT; Letai, A; Look, AT; Mansour, MR; Montero, J; Ng, CE; Reed, C; Rodig, SJ; Shacham, S; Stone, RM; Wang, JC1
Abboud, C; Araujo, S; Bennett, J; Chan, G; Chen, CY; Cheng, G; Chiou, TJ; Dougherty, S; Feigert, J; Giagounidis, A; Gorin, NC; Götze, K; Greenberg, P; Jang, JH; Johnson, B; Kambhampati, S; Kamel, YM; Kim, YJ; Lee, JH; Lyons, R; Mannino, F; Platzbecker, U; Ruggeri, M; Santini, V; Stone, N; Verma, A; Wong, RS; Yeh, SP1
Brandwein, JM; Chow, S; Gupta, V; Hedley, D; Sanfelice, D; Schimmer, AD; Schuh, AC; Seftel, MD; Shamas-Din, A; Yee, KW1
Adams, DF; Sellers, TS1
Baloglu, E; Berezovskaya, A; Conway, AS; Etchin, J; Galinsky, IA; Kauffman, M; Landesman, Y; Look, AT; Senapedis, W; Shacham, S; Stone, RM; Wang, JC1
Bhatnagar, B; Blum, W; Dorrance, AM; Garzon, R; Kashyap, T; Kauffman, M; Lai, TH; Landesman, Y; McNeil, B; Meng, X; Ranganathan, P; Sampath, D; Shacham, S; Yu, X1
Altman, J; Dinner, S; Frankfurt, O; Gao, J; Helenowski, I; McMahon, BJ; Stein, BL; Waisbren, J1
Adane, B; Alvarez-Calderon, F; D'Alessandro, A; DeGregori, J; Gregory, MA; Hansen, KC; Jordan, CT; Kim, J; Kumar, A; Kumar, V; Nemkov, T; Pollyea, DA; Rozhok, AI; Serkova, NJ; Tan, AC; Wempe, MF1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A1
Gore, SD1
Adams, JA; Liu Yin, JA; Morris, KL1
Giles, FJ1
Albitar, M; Boskovic, D; Brandwein, J; Cahill, A; DeAngelo, D; Giles, F; Kell, J; O'Brien, S; Pigneux, A; Robak, T; Seiter, K; Staib, P; Stock, W; Stuart, R; Tallman, M; Thomas, X; Vey, N1
Aivado, MA; Bruns, I; Erickson-Miller, CL; Kawahara, M; Luciano, JP; Parekh, S; Steidl, U; Verma, A; Will, B1
Albitar, MX; Cahill, AL; Deangelo, DJ; Giles, FJ; Karsten, V; Kell, J; O'Brien, SM; Pigneux, A; Schiller, GJ; Solomon, S; Stuart, RK; Vey, N1
Chen, H; Deisseroth, A; Farrell, A; He, K; Justice, R; Kane, R; Pazdur, R; Sridhara, R1
Giles, F; Vey, N1
Aivado, M; Chadderton, A; Erickson-Miller, CL; Kirchner, J; May, R; Payne, P1
Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A1
Kuter, DJ1
Amin, S; Hori, T; Hu, CD; Kester, M; Khan, O; Park, S; Sharma, AK; Takahashi, Y; Wang, HG; Young, MM; Yun, J; Zhang, J1
Carroll, M; Gewirtz, AM; Kalota, A; Sugita, M1
FREI, E; FREIREICH, EJ; KARON, M1
HOLLAND, JR; REGELSON, W1
Advani, A; Albitar, M; Bilgrami, SF; Cahill, A; Daenen, SM; Faderl, S; Ferrant, A; Giles, F; Kantarjian, H; Karp, J; Karsten, V; Khan, KD; Mufti, G; O'Brien, S; Ravandi, F; Rizzieri, D; Roboz, G; Verhoef, G; Vey, N; Wijermans, P1
Craig, CM; Schiller, GJ1
Akin, DT; Barton, JC; Gilbert, CS; Kinkade, JM; Parmley, RT1
Bricteux, N; Focan, C; Hugues, J; Jardon-Jeghers, C1
Böhnel, J; Stacher, A1
Clément, F1
Hamilton, WC; La Placa, SJ1

Reviews

8 review(s) available for hydrazine and Leukemia, Myeloid, Acute

ArticleYear
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    The Cochrane database of systematic reviews, 2017, 09-30, Volume: 9

    Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin

2017
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
    Cancer, 2019, Sep-15, Volume: 125, Issue:18

    Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles

2019
Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:12

    Topics: Antineoplastic Agents; Benzoates; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Hematologic Diseases; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin; Thrombocytopenia

2013
[Novel medical treatment modalities in hematology].
    Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24

    Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine

2008
Laromustine (cloretazine).
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:4

    Topics: Aged; Animals; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Humans; Hydrazines; Leukemia, Myeloid, Acute; Remission Induction; Sulfonamides; Treatment Outcome

2010
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
    Current medicinal chemistry, 2011, Volume: 18, Issue:5

    Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1

2011
What is the potential for thrombopoietic agents in acute leukemia?
    Best practice & research. Clinical haematology, 2011, Volume: 24, Issue:4

    Topics: Adult; Benzoates; Blood Platelets; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; Hydrazines; Leukemia, Myeloid, Acute; Molecular Mimicry; Platelet Count; Polyethylene Glycols; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recombinant Proteins; Remission Induction; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Time Factors

2011
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
    Blood reviews, 2008, Volume: 22, Issue:4

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides

2008

Trials

17 trial(s) available for hydrazine and Leukemia, Myeloid, Acute

ArticleYear
Efficacy and safety of selinexor in the treatment of AML: A protocol for systematic review and meta-analysis.
    Medicine, 2021, Dec-10, Volume: 100, Issue:49

    Topics: Adult; Aged; Humans; Hydrazines; Leukemia, Myeloid, Acute; Meta-Analysis as Topic; Systematic Reviews as Topic; Triazoles

2021
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
    Leukemia, 2022, Volume: 36, Issue:9

    Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Triazoles

2022
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 01-01, Volume: 26, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Patient Safety; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles

2020
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.
    Haematologica, 2020, Volume: 105, Issue:8

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Filgrastim; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Mice, Inbred C57BL; Middle Aged; Remission Induction; Treatment Outcome; Triazoles; Young Adult

2020
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:8

    Topics: Azacitidine; Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia; Treatment Outcome

2020
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.
    Bone marrow transplantation, 2020, Volume: 55, Issue:11

    Topics: Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transplantation Conditioning; Triazoles

2020
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
    British journal of haematology, 2020, Volume: 190, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Recurrence; Salvage Therapy; Triazoles

2020
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
    The Lancet. Haematology, 2020, Volume: 7, Issue:8

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Patient Safety; Prognosis; Survival Rate; Triazoles

2020
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Annals of hematology, 2021, Volume: 100, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Triazoles; Vidarabine

2021
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
    Blood, 2017, 06-15, Volume: 129, Issue:24

    Topics: Adult; Blast Crisis; Bone Marrow Cells; Disease-Free Survival; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Triazoles

2017
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    The Lancet. Haematology, 2018, Volume: 5, Issue:1

    Topics: Aged; Benzoates; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Placebos; Pyrazoles; Safety; Thrombocytopenia

2018
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
    Journal for immunotherapy of cancer, 2019, 07-10, Volume: 7, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Drug Resistance, Neoplasm; Female; Galectins; Hepatitis A Virus Cellular Receptor 2; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; T-Lymphocyte Subsets; Treatment Failure; Triazoles

2019
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    The Lancet. Haematology, 2015, Volume: 2, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Benzoates; Double-Blind Method; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome

2015
A phase I study of elesclomol sodium in patients with acute myeloid leukemia.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:10

    Topics: Aged; Antineoplastic Agents; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome

2016
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
    Blood, 2009, Nov-05, Volume: 114, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Humans; Hydrazines; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Sulfonamides; Young Adult

2009
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-10, Volume: 28, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Comorbidity; Europe; Female; Gene Expression Regulation, Leukemic; Heart Diseases; Humans; Hydrazines; Infusions, Intravenous; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Liver Diseases; Lung Diseases; Male; Middle Aged; Prospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Treatment Outcome; United States

2010
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jan-01, Volume: 25, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Chemical; Prognosis; Remission Induction; Risk; Sulfonamides; Time Factors; Treatment Outcome

2007

Other Studies

39 other study(ies) available for hydrazine and Leukemia, Myeloid, Acute

ArticleYear
Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance.
    Cell reports, 2022, 08-09, Volume: 40, Issue:6

    Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Hydrazines; Leukemia, Myeloid, Acute; Proteome; Proto-Oncogene Proteins c-akt; Triazoles; Tumor Suppressor Protein p53

2022
Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study.
    Acta haematologica, 2023, Volume: 146, Issue:5

    Topics: Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Leukopenia; Myelodysplastic Syndromes; Thrombocytopenia; Treatment Outcome

2023
Concerning survival signal for eltrombopag in MDS/AML.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:4

    Topics: Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Pyrazoles

2020
Distinctive and common features of moderate aplastic anaemia.
    British journal of haematology, 2020, Volume: 189, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anemia, Aplastic; Autoimmune Diseases; Benzoates; Blood Transfusion; Bone Marrow; Child; Child, Preschool; Clonal Evolution; Combined Modality Therapy; Danazol; Disease Management; Disease Progression; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pyrazoles; Severity of Illness Index; Young Adult

2020
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
    Blood, 2020, 07-02, Volume: 136, Issue:1

    Topics: Age of Onset; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Benzoates; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 7; Clonal Evolution; Clone Cells; Disease Progression; Granulocyte Colony-Stimulating Factor; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Leukemia, Myeloid, Acute; Models, Biological; Monosomy; Mutation; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Pyrazoles; Selection, Genetic; Telomere Shortening

2020
A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoates; Consolidation Chemotherapy; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Pyrazoles

2020
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome.
    Haematologica, 2020, 12-01, Volume: 105, Issue:12

    Topics: Benzoates; Hematopoiesis; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles

2020
Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
    Cancer letters, 2018, 01-28, Volume: 413

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Synergism; Energy Metabolism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; Female; Histone Demethylases; Histones; HL-60 Cells; Humans; Hydrazines; Leukemia, Myeloid, Acute; Methylation; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Morpholines; Proto-Oncogene Proteins c-bcl-2; Pyridones; Sulfonamides; Time Factors; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays

2018
LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells.
    British journal of haematology, 2018, Volume: 183, Issue:3

    Topics: Animals; Histone Demethylases; Humans; Hydrazines; Leukemia, Myeloid, Acute; Mice; Neoplasm Proteins; Sulfonamides; THP-1 Cells; Xenograft Model Antitumor Assays

2018
Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML.
    The Lancet. Haematology, 2018, Volume: 5, Issue:1

    Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Risk; Thrombocytopenia

2018
Mutant NPM1 Maintains the Leukemic State through HOX Expression.
    Cancer cell, 2018, 09-10, Volume: 34, Issue:3

    Topics: Aged; Animals; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Down-Regulation; Exportin 1 Protein; Female; Gene Expression Regulation, Leukemic; Homeodomain Proteins; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mutation; Nuclear Proteins; Nucleophosmin; Proteolysis; Receptors, Cytoplasmic and Nuclear; Triazoles; Xenograft Model Antitumor Assays

2018
Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
    Journal of cellular and molecular medicine, 2018, Volume: 22, Issue:12

    Topics: Adult; Aged; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Triazoles

2018
Eltrombopag use in higher risk myeloid cancers: fitting a square "pag" into a round hole?
    The Lancet. Haematology, 2019, Volume: 6, Issue:3

    Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Risk

2019
Eltrombopag and serum of a different hue.
    Archives of pathology & laboratory medicine, 2013, Volume: 137, Issue:9

    Topics: Aged; Aged, 80 and over; Benzoates; Bilirubin; Humans; Hydrazines; Hydrogen-Ion Concentration; Leukemia, Myeloid, Acute; Pigmentation; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia

2013
Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Benzoates; Cell Line, Tumor; Cell Proliferation; Clonal Evolution; Female; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Megakaryocyte Progenitor Cells; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thalidomide; Thrombopoiesis

2014
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
    Leukemia, 2014, Volume: 28, Issue:11

    Topics: Animals; Apoptosis; Cells, Cultured; Co-Repressor Proteins; Disease Models, Animal; Enzyme Inhibitors; Female; Histone Acetyltransferases; Histone Demethylases; Histones; Humans; Hydrazines; Leukemia, Myeloid, Acute; Mice, Inbred NOD; Mice, SCID; Nerve Tissue Proteins; Nucleophosmin; RNA, Small Interfering; Stem Cells; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines.
    The Journal of pharmacology and experimental therapeutics, 2015, Volume: 352, Issue:3

    Topics: Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; HL-60 Cells; Humans; Hydrazines; Leukemia, Myeloid, Acute; Phosphotransferases (Alcohol Group Acceptor); Pyrazoles; U937 Cells

2015
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
    Blood, 2015, Apr-23, Volume: 125, Issue:17

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; DNA Modification Methylases; Exportin 1 Protein; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Cells, Cultured; Up-Regulation

2015
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.
    Leukemia, 2016, Volume: 30, Issue:1

    Topics: Animals; Exportin 1 Protein; Humans; Hydrazines; Immunosuppression Therapy; Karyopherins; Leukemia, Myeloid, Acute; Mice; Neoplastic Stem Cells; Receptors, Cytoplasmic and Nuclear; Triazoles; Xenograft Model Antitumor Assays

2016
Eltrombopag: Investigation of Previously Reported Serum Discoloration and Negative Interference on a Total Bilirubin Diazo Method.
    Archives of pathology & laboratory medicine, 2016, Volume: 140, Issue:5

    Topics: Adult; Azo Compounds; Benzoates; Bilirubin; Color; Coloring Agents; Diagnosis, Differential; Hematinics; Humans; Hydrazines; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Osmolar Concentration; Pyrazoles; Receptors, Thrombopoietin; Reproducibility of Results; Serum; Spectrophotometry; Thrombocytopenia

2016
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
    Leukemia, 2017, Volume: 31, Issue:1

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Blast Crisis; Carcinogenesis; Exportin 1 Protein; Hematopoietic Stem Cells; Heterografts; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Receptors, Cytoplasmic and Nuclear; Triazoles

2017
XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-15, Volume: 22, Issue:24

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Nucleus; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Proto-Oncogene Proteins c-myc; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Topoisomerase II Inhibitors; Triazoles

2016
Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
    International journal of hematology, 2017, Volume: 105, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Risk; Thrombocytopenia; Thrombopoietin

2017
ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.
    Proceedings of the National Academy of Sciences of the United States of America, 2016, 10-25, Volume: 113, Issue:43

    Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzothiazoles; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Glucosephosphate Dehydrogenase; Humans; Hydrazines; Leukemia, Myeloid, Acute; Mice, Inbred NOD; Middle Aged; Oxidation-Reduction; Phenylurea Compounds; Protein Kinase Inhibitors; RNA, Small Interfering; Signal Transduction; Survival Analysis; Xenograft Model Antitumor Assays

2016
New agents for the treatment of AML recent study findings.
    Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11

    Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide

2008
Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
    Leukemia research, 2009, Volume: 33, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; Leukemia, Myeloid, Acute; Sulfonamides

2009
Laromustine: the return of alkylators to non-myeloablative therapy of AML.
    Leukemia research, 2009, Volume: 33, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; Leukemia, Myeloid, Acute; Sulfonamides

2009
Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
    Blood, 2009, Oct-29, Volume: 114, Issue:18

    Topics: Animals; Apoptosis; Benzoates; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Hematopoiesis; Humans; Hydrazines; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Megakaryocytes; Mice; Mice, Inbred NOD; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Xenograft Model Antitumor Assays

2009
Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia.
    Blood, 2010, Jan-14, Volume: 115, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Humans; Hydrazines; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Sulfonamides

2010
Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag.
    Leukemia research, 2010, Volume: 34, Issue:9

    Topics: Base Sequence; Benzoates; Cell Line, Tumor; Cell Proliferation; DNA Primers; Humans; Hydrazines; Leukemia; Leukemia, Myeloid, Acute; Lymphoma; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction

2010
Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis.
    The Journal of biological chemistry, 2012, Apr-06, Volume: 287, Issue:15

    Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Proteins; Caspase 3; Caspase 8; Cell Membrane; Cell Survival; Cells, Cultured; Death Domain Receptor Signaling Adaptor Proteins; Enzyme Activation; Fas-Associated Death Domain Protein; Gene Knockout Techniques; Heat-Shock Proteins; Humans; Hydrazines; Leukemia, Myeloid, Acute; Lysosomal Membrane Proteins; Mice; Microtubule-Associated Proteins; Mitochondria; Phosphotransferases (Alcohol Group Acceptor); Protein Binding; Protein Multimerization; Protein Transport; Pyrazoles; Sequestosome-1 Protein; Tumor Cells, Cultured; Ubiquitin-Conjugating Enzymes

2012
Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression.
    Leukemia, 2013, Volume: 27, Issue:5

    Topics: Benzoates; Cell Line, Tumor; Cell Survival; Humans; Hydrazines; Leukemia, Myeloid, Acute; Pyrazoles; Receptors, Thrombopoietin

2013
Methylglyoxal bis (guanylhydrazone): a new agent active against acute myelocytic leukemia.
    Cancer chemotherapy reports, 1962, Volume: 16

    Topics: Amidines; Antineoplastic Agents; Humans; Hydrazines; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mitoguazone; Pyruvaldehyde

1962
Clinical experience with methylglyoxal bis (guanylhydrazone) dihydrochloride: a new agent with clinical activity in acute myelocytic leukemia and the lymphomas.
    Cancer chemotherapy reports, 1963, Volume: 27

    Topics: Antineoplastic Agents; Humans; Hydrazines; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Pyruvaldehyde

1963
Cytochemistry and ultrastructural morphometry of cultured HL60 myeloid leukemia cells.
    Cancer research, 1987, Sep-15, Volume: 47, Issue:18

    Topics: 3,3'-Diaminobenzidine; Cells, Cultured; Cytoplasmic Granules; Eosinophils; Golgi Apparatus; Histocytochemistry; Humans; Hydrazines; Leukemia, Myeloid, Acute

1987
[Hodgkin's disease complicated by myeloblastic leukosis].
    Revue medicale de Liege, 1973, Jun-15, Volume: 28, Issue:12

    Topics: Adult; Biopsy; Hodgkin Disease; Humans; Hydrazines; Leukemia, Myeloid, Acute; Lymph Nodes; Male; Mechlorethamine; Methylprednisolone; Radiography; Vinblastine; Vincristine

1973
[On the effect of a cytostatic of the methylhydrazine group on malignant hemoblastomas].
    Wiener medizinische Wochenschrift (1946), 1966, May-21, Volume: 116, Issue:21

    Topics: Adult; Aged; Antineoplastic Agents; Female; Hodgkin Disease; Humans; Hydrazines; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphatic Diseases; Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melanoma

1966
[Therapy of malignant hemopathies].
    Praxis, 1966, Jun-16, Volume: 55, Issue:24

    Topics: Female; Hematologic Diseases; Humans; Hydrazines; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Multiple Myeloma; Prednisone

1966
The crystal and molecular structure of an anti-leukemia drug: methylglyoxal bisguanylhydrazone dihydrochloride monohydrate, C5N8H12. 2HC1. H2O. neutron and x-ray diffraction studies.
    Acta crystallographica. Section B: Structural crystallography and crystal chemistry, 1968, Sep-15, Volume: 24, Issue:9

    Topics: Antineoplastic Agents; Chemical Phenomena; Chemistry; Humans; Hydrazines; Leukemia, Myeloid, Acute; Neutrons; X-Ray Diffraction

1968